| US 7,595,316 B2 | ||
| Heteroaryloxy nitrogenous saturated heterocyclic derivative | ||
| Norikazu Ohtake, Tsukuba (Japan); Akira Naya, Tsukuba (Japan); Yuji Haga, Tsukuba (Japan); Makoto Jitsuoka, Moriya (Japan); Takuya Suga, Tsukuba (Japan); Ryo Yoshimoto, Tsukuba (Japan); Shigeru Tokita, Tsukuba (Japan); and Akio Kanatani, Ushiku (Japan) | ||
| Assigned to Banyu Pharmaceutical Co., Ltd., Tokyo (Japan) | ||
| Appl. No. 10/561,115 PCT Filed Jun. 24, 2004, PCT No. PCT/JP2004/009272 § 371(c)(1), (2), (4) Date Dec. 15, 2005, PCT Pub. No. WO2005/007644, PCT Pub. Date Jan. 27, 2005. |
||
| Claims priority of application No. 2003-184879 (JP), filed on Jun. 27, 2003. | ||
| Prior Publication US 2006/0178375 A1, Aug. 10, 2006 | ||
| Int. Cl. A01N 43/58 (2006.01); A61K 31/50 (2006.01); C07D 239/00 (2006.01); C07D 239/02 (2006.01) | ||
| U.S. Cl. 514—247 [544/242] | 8 Claims |
1. A compound of the formula (I):
 wherein:
R is selected from the group consisting of:
a linear or branched C2-6alkyl group, and a cycloalkyl group having from 3 to 9 carbon atoms,
which is unsubstituted or substituted with a group selected from the group consisting of: a cyano group; a hydroxyl group;
a lower alkyl group optionally substituted with a hydroxyl group, a halogen atom or an amino group; a lower alkoxy group optionally
substituted with a halogen atom; a halogen atom; a mono-lower alkylaminocarbonyloxy group; a di-lower alkylaminocarbonyloxy
group; a mono-lower alkylcarbamoyl group; a di-lower alkylcarbamoyl group; a carbamoyl group; a cycloalkyliminocarbonyl group;
and a trifluoromethyl group,
Y is selected from the group consisting of:
(1) a phenyl group, a pyridyl group and a pyrimidinyl group;
which may have 1 or 2 substituents selected from the group consisting of: a hydroxyl group; a lower alkyl group optionally
substituted with a hydroxy group, a halogen atom or an amino group; a lower alkoxy group optionally substituted with a halogen
atom; a lower alkylsulfonyl group; a cyclo-lower alkylsulfonyl group; a halogen atom; a mono-lower alkylaminocarbonyloxy group;
a di-lower alkylaminocarbonyloxy group; a mono-lower alkylcarbamoyl group; a di-lower alkylcarbamoyl group; a cycloalkyliminocarbamoyl
group; a lactam ring; a mono-lower alkylamino group; a di-lower alkylamino group; an alkanoyl group; an alkoxycarbonylamino
group wherein the nitrogen atom optionally substituted with a lower alkyl group; an alkanoylamino group wherein the nitrogen
atom is optionally substituted with a lower alkyl group; and an alkylsulfonylamino group wherein the nitrogen atom is optionally
substituted with a lower alkyl group;
(2) a bi-cyclic condensed ring selected from a group consisting of:
naphthyl, quinolinyl, indolyl, [1,2,4]-triazolo[4,3-a]pyridine and dibenzo[b,d]furan;
which may have 1 or 2 substituents selected from the group consisting of: a hydroxyl group; a lower alkyl group optionally
substituted with a hydroxy group, a halogen atom or an amino group; a lower alkoxy group optionally substituted with a halogen
atom; a lower alkylsulfonyl group; a cyclo-lower alkylsulfonyl group; a halogen atom; a mono-lower alkylaminocarbonyloxy group;
a di-lower alkylaminocarbonyloxy group; a mono-lower alkylcarbamoyl group; a di-lower alkylcarbamoyl group; a cycloalkyliminocarbamoyl
group; a lactam ring; a mono-lower alkylamino group; a di-lower alkylamino group; an alkanoyl group; an alkoxycarbonylamino
group wherein the nitrogen atom is optionally substituted with a lower alkyl group; an alkanoylamino group wherein the nitrogen
atom is optionally substituted with a lower alkyl group; and an alkylsulfonylamino group wherein the nitrogen atom is optionally
substituted with a lower alkyl group;
(3) a thienyl group;
which may have 1 or 2 substituents selected from the group consisting of: a hydroxyl group; a lower alkyl group optionally
substituted with a hydroxy group, a halogen atom or an amino group; a lower alkoxy group optionally substituted with a halogen
atom; a lower alkylsulfonyl group; a cyclo-lower alkylsulfonyl group; a halogen atom; a mono-lower alkylaminocarbonyloxy group;
a di-lower alkylaminocarbonyloxy group; a mono-lower alkylcarbamoyl group; a di-lower alkylcarbamoyl group; a cycloalkyliminocarbamoyl
group; a lactam ring; a mono-lower alkylamino group; a di-lower alkylamino group; an alkanoyl group; an alkoxycarbonylamino
group wherein the nitrogen atom is optionally substituted with a lower alkyl group; an alkanoylamino group wherein the nitrogen
atom is optionally substituted with a lower alkyl group; and an alkylsulfonylamino group wherein the nitrogen atom is optionally
substituted with a lower alkyl group;
(4) a piperidinyl group;
which may have 1 or 2 substituents selected from the group consisting of: a hydroxyl group; a lower alkyl group optionally
substituted with a hydroxy group, a halogen atom or an amino group; a lower alkoxy group optionally substituted with a halogen
atom; a halogen atom; a mono-lower alkylaminocarbonyloxy group; a di-lower alkylaminocarbonyloxy group; a mono-lower alkylcarbamoyl
group; a di-lower alkylcarbamoyl group; a cycloalkyliminocarbamoyl group; a lactam ring; a mono-lower alkylamino group; a
di-lower alkylamino group; an alkanoyl group; an alkoxycarbonylamino group wherein the nitrogen atom is optionally substituted
with a lower alkyl group; an alkanoylamino group wherein the nitrogen atom is optionally substituted with a lower alkyl group;
and an alkylsulfonylamino group wherein the nitrogen atom is optionally substituted with a lower alkyl group;
(5) a group of the formula (IV-2):
 and
(6) a group of the formula (Q1-1):
 wherein R7 represents a hydrogen atom, a lower alkyl group, a cyclo-lower alkyl group, a halo-lower alkyl group, or an aralkyl group;
or a pharmaceutically acceptable salt thereof.
|